Related Experiment Video
Updated: Aug 20, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Treatment of acute and chronic hepatitis C
1Section of Hepatobiliary Diseases, Department of Medicine, University of Florida College of Medicine, Gainesville, FL 32610-0214, USA.
Abstract:
Interferon is currently the only available treatment for chronic hepatitis C but is effective in only about 40% of patients. Most of these responding patients relapse after short courses, so that sustained long-term viral-negative responses are uncommon (10% to 20%). However, longer treatment courses have significantly reduced relapse, thereby increasing sustained response rates. Furthermore, the combination of ribavirin with interferon shows promise for reducing relapse even further. The challenge for the future is to develop antiviral agents that will be effective in the large proportion of patients who do not respond to interferon.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Antiviral Nucleoside Inhibitors
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
